RxDoctor Payments Data

Josef Gutman, MD

Neurology · East Meadow, NYNPI 1972867265

Payments from drug & device makers

$134,617in general payments, 2019–2025

Across 48 payments — averaging $2804.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$67K
  • Novartis$53K
  • Biogen$14K
  • Amgen$315
  • TG Therapeutics, Inc.$233
  • Sanofi$157
  • plus $408 from 12 others

What the payments were for

  • Consulting fees$30017%
  • Speaking & faculty fees$1498%
  • Food & beverage$1,33975%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$134,617 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$87,765
Medicare patients
246
Services billed
1,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AubagioTeriflunomide55$531,673
TecfideraDimethyl Fumarate32$396,433
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5024$394,093
VumerityDiroximel Fumarate36$354,038
Kesimpta PenOfatumumab19$168,769
Gamunex-CImmune Globul G/Gly/Iga Avg 4649$161,772
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5033$146,506
RebifInterferon Beta-1a/Albumin13$137,402
CopaxoneGlatiramer Acetate16$136,699
ZeposiaOzanimod Hydrochloride13$119,489
Teriflunomide52$116,279
Dalfampridine ErDalfampridine132$83,654
Glatiramer Acetate13$45,112
Wellbutrin XlBupropion Hcl11$34,352
QuliptaAtogepant12$25,051

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera, Vumerity$13,950$750,47168 claims
SanofiAubagio$157$531,67355 claims
EMD Serono, Inc.Rebif$65$137,40213 claims
AbbVieQulipta$89$25,05112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,623 neurology providers in New York.

Other neurology in East Meadow

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →